Humoral Immune Responses after an Omicron-Adapted Booster BNT162b2 Vaccination in Patients with Lymphoid Malignancies

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Humoral Immune Responses after an Omicron-Adapted Booster BNT162b2 Vaccination in Patients with Lymphoid Malignancies. / Heftdal, Line Dam; Hansen, Cecilie Bo; Hamm, Sebastian Rask; Pérez-Alós, Laura; Fogh, Kamille; Pries-Heje, Mia; Hasselbalch, Rasmus Bo; Møller, Dina Leth; Gang, Anne Ortved; Ostrowski, Sisse Rye; Frikke-Schmidt, Ruth; Sørensen, Erik; Hilsted, Linda; Bundgaard, Henning; Garred, Peter; Iversen, Kasper; Sabin, Caroline; Nielsen, Susanne Dam; Grønbæk, Kirsten.

In: Viruses, Vol. 16, No. 1, 11, 2024.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Heftdal, LD, Hansen, CB, Hamm, SR, Pérez-Alós, L, Fogh, K, Pries-Heje, M, Hasselbalch, RB, Møller, DL, Gang, AO, Ostrowski, SR, Frikke-Schmidt, R, Sørensen, E, Hilsted, L, Bundgaard, H, Garred, P, Iversen, K, Sabin, C, Nielsen, SD & Grønbæk, K 2024, 'Humoral Immune Responses after an Omicron-Adapted Booster BNT162b2 Vaccination in Patients with Lymphoid Malignancies', Viruses, vol. 16, no. 1, 11. https://doi.org/10.3390/v16010011

APA

Heftdal, L. D., Hansen, C. B., Hamm, S. R., Pérez-Alós, L., Fogh, K., Pries-Heje, M., Hasselbalch, R. B., Møller, D. L., Gang, A. O., Ostrowski, S. R., Frikke-Schmidt, R., Sørensen, E., Hilsted, L., Bundgaard, H., Garred, P., Iversen, K., Sabin, C., Nielsen, S. D., & Grønbæk, K. (2024). Humoral Immune Responses after an Omicron-Adapted Booster BNT162b2 Vaccination in Patients with Lymphoid Malignancies. Viruses, 16(1), [11]. https://doi.org/10.3390/v16010011

Vancouver

Heftdal LD, Hansen CB, Hamm SR, Pérez-Alós L, Fogh K, Pries-Heje M et al. Humoral Immune Responses after an Omicron-Adapted Booster BNT162b2 Vaccination in Patients with Lymphoid Malignancies. Viruses. 2024;16(1). 11. https://doi.org/10.3390/v16010011

Author

Heftdal, Line Dam ; Hansen, Cecilie Bo ; Hamm, Sebastian Rask ; Pérez-Alós, Laura ; Fogh, Kamille ; Pries-Heje, Mia ; Hasselbalch, Rasmus Bo ; Møller, Dina Leth ; Gang, Anne Ortved ; Ostrowski, Sisse Rye ; Frikke-Schmidt, Ruth ; Sørensen, Erik ; Hilsted, Linda ; Bundgaard, Henning ; Garred, Peter ; Iversen, Kasper ; Sabin, Caroline ; Nielsen, Susanne Dam ; Grønbæk, Kirsten. / Humoral Immune Responses after an Omicron-Adapted Booster BNT162b2 Vaccination in Patients with Lymphoid Malignancies. In: Viruses. 2024 ; Vol. 16, No. 1.

Bibtex

@article{39383ebb8c2c435eaf79ee2cf29cdea0,

title = "Humoral Immune Responses after an Omicron-Adapted Booster BNT162b2 Vaccination in Patients with Lymphoid Malignancies",

abstract = "To accommodate waning COVID-19 vaccine immunity to emerging SARS-CoV-2 variants, variant-adapted mRNA vaccines have been introduced. Here, we examine serological responses to the BA.1 and BA.4-5 Omicron variant-adapted BNT162b2 COVID-19 vaccines in people with lymphoid malignancies. We included 233 patients with lymphoid malignancies (chronic lymphocytic B-cell leukemia: 73 (31.3%), lymphoma: 89 (38.2%), multiple myeloma/amyloidosis: 71 (30.5%)), who received an Omicron-adapted mRNA-based COVID-19 vaccine. IgG and neutralizing antibodies specific for the receptor-binding domain (RBD) of SARS-CoV-2 were measured using ELISA-based methods. Differences in antibody concentrations and neutralizing capacity and associations with risk factors were assessed using mixed-effects models. Over the period of vaccination with an Omicron-adapted COVID-19 vaccine, the predicted mean concentration of anti-RBD IgG increased by 0.09 log10 AU/mL/month (95% CI: 0.07; 0.11) in patients with lymphoid malignancies across diagnoses. The predicted mean neutralizing capacity increased by 0.9 percent points/month (95% CI: 0.2; 1.6). We found no associations between the increase in antibody concentration or neutralizing capacity and the variant included in the adapted vaccine. In conclusion, a discrete increase in antibody concentrations and neutralizing capacity was found over the course of Omicron-adapted vaccination in patients with lymphoid malignancies regardless of the adapted vaccine variant, indicating a beneficial effect of Omicron-adapted booster vaccination in this population.",

keywords = "booster, COVID-19, lymphoid malignancies, SARS-CoV-2, vaccine, variant",

author = "Heftdal, {Line Dam} and Hansen, {Cecilie Bo} and Hamm, {Sebastian Rask} and Laura P{\'e}rez-Al{\'o}s and Kamille Fogh and Mia Pries-Heje and Hasselbalch, {Rasmus Bo} and M{\o}ller, {Dina Leth} and Gang, {Anne Ortved} and Ostrowski, {Sisse Rye} and Ruth Frikke-Schmidt and Erik S{\o}rensen and Linda Hilsted and Henning Bundgaard and Peter Garred and Kasper Iversen and Caroline Sabin and Nielsen, {Susanne Dam} and Kirsten Gr{\o}nb{\ae}k",

note = "Publisher Copyright: {\textcopyright} 2023 by the authors.",

year = "2024",

doi = "10.3390/v16010011",

language = "English",

volume = "16",

journal = "Viruses",

issn = "1999-4915",

publisher = "M D P I AG",

number = "1",

}

RIS

TY - JOUR

T1 - Humoral Immune Responses after an Omicron-Adapted Booster BNT162b2 Vaccination in Patients with Lymphoid Malignancies

AU - Heftdal, Line Dam

AU - Hansen, Cecilie Bo

AU - Hamm, Sebastian Rask

AU - Pérez-Alós, Laura

AU - Fogh, Kamille

AU - Pries-Heje, Mia

AU - Hasselbalch, Rasmus Bo

AU - Møller, Dina Leth

AU - Gang, Anne Ortved

AU - Ostrowski, Sisse Rye

AU - Frikke-Schmidt, Ruth

AU - Sørensen, Erik

AU - Hilsted, Linda

AU - Bundgaard, Henning

AU - Garred, Peter

AU - Iversen, Kasper

AU - Sabin, Caroline

AU - Nielsen, Susanne Dam

AU - Grønbæk, Kirsten

PY - 2024

Y1 - 2024

N2 - To accommodate waning COVID-19 vaccine immunity to emerging SARS-CoV-2 variants, variant-adapted mRNA vaccines have been introduced. Here, we examine serological responses to the BA.1 and BA.4-5 Omicron variant-adapted BNT162b2 COVID-19 vaccines in people with lymphoid malignancies. We included 233 patients with lymphoid malignancies (chronic lymphocytic B-cell leukemia: 73 (31.3%), lymphoma: 89 (38.2%), multiple myeloma/amyloidosis: 71 (30.5%)), who received an Omicron-adapted mRNA-based COVID-19 vaccine. IgG and neutralizing antibodies specific for the receptor-binding domain (RBD) of SARS-CoV-2 were measured using ELISA-based methods. Differences in antibody concentrations and neutralizing capacity and associations with risk factors were assessed using mixed-effects models. Over the period of vaccination with an Omicron-adapted COVID-19 vaccine, the predicted mean concentration of anti-RBD IgG increased by 0.09 log10 AU/mL/month (95% CI: 0.07; 0.11) in patients with lymphoid malignancies across diagnoses. The predicted mean neutralizing capacity increased by 0.9 percent points/month (95% CI: 0.2; 1.6). We found no associations between the increase in antibody concentration or neutralizing capacity and the variant included in the adapted vaccine. In conclusion, a discrete increase in antibody concentrations and neutralizing capacity was found over the course of Omicron-adapted vaccination in patients with lymphoid malignancies regardless of the adapted vaccine variant, indicating a beneficial effect of Omicron-adapted booster vaccination in this population.

AB - To accommodate waning COVID-19 vaccine immunity to emerging SARS-CoV-2 variants, variant-adapted mRNA vaccines have been introduced. Here, we examine serological responses to the BA.1 and BA.4-5 Omicron variant-adapted BNT162b2 COVID-19 vaccines in people with lymphoid malignancies. We included 233 patients with lymphoid malignancies (chronic lymphocytic B-cell leukemia: 73 (31.3%), lymphoma: 89 (38.2%), multiple myeloma/amyloidosis: 71 (30.5%)), who received an Omicron-adapted mRNA-based COVID-19 vaccine. IgG and neutralizing antibodies specific for the receptor-binding domain (RBD) of SARS-CoV-2 were measured using ELISA-based methods. Differences in antibody concentrations and neutralizing capacity and associations with risk factors were assessed using mixed-effects models. Over the period of vaccination with an Omicron-adapted COVID-19 vaccine, the predicted mean concentration of anti-RBD IgG increased by 0.09 log10 AU/mL/month (95% CI: 0.07; 0.11) in patients with lymphoid malignancies across diagnoses. The predicted mean neutralizing capacity increased by 0.9 percent points/month (95% CI: 0.2; 1.6). We found no associations between the increase in antibody concentration or neutralizing capacity and the variant included in the adapted vaccine. In conclusion, a discrete increase in antibody concentrations and neutralizing capacity was found over the course of Omicron-adapted vaccination in patients with lymphoid malignancies regardless of the adapted vaccine variant, indicating a beneficial effect of Omicron-adapted booster vaccination in this population.

KW - booster

KW - COVID-19

KW - lymphoid malignancies

KW - SARS-CoV-2

KW - vaccine

KW - variant

U2 - 10.3390/v16010011

DO - 10.3390/v16010011

M3 - Journal article

C2 - 38275946

AN - SCOPUS:85183394609

VL - 16

JO - Viruses

JF - Viruses

SN - 1999-4915

IS - 1

M1 - 11

ER -

ID: 381885881